Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST) Meeting Abstract
| Authors: | Janku, F.; Heinrich, M.; Razak, A.; Gordon, M.; Chi, P.; Ganjoo, K.; von Mehren, M.; Somaiah, N.; Lee, J.; Kuida, K.; Soto, R. R.; Rosen, O.; George, S. |
| Abstract Title: | Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST) |
| Meeting Title: | 109th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2018 Apr 14-18 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-07-01 |
| Language: | English |
| ACCESSION: | WOS:000468818900028 |
| DOI: | 10.1158/1538-7445.Am2018-ct029 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CT029 -- Source: Wos |
